<DOC>
	<DOCNO>NCT00937352</DOCNO>
	<brief_summary>The purpose study ass long-term safety tolerability Bapineuzumab ( AAB-001 , ELN115727 ) subject Alzheimer 's disease participate study ELN115727-301 study ELN115727-302 .</brief_summary>
	<brief_title>A Long-Term Safety Tolerability Study Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD Must complete study 301 study 302 ; complete Visit 15 ( Week 78 ) Brain MRI scan evaluate safety Study 301 302 Visit 14/Week 71 Caregiver able attend clinic visit patient Any new medical contraindication clinically significant abnormality physical , neurological , laboratory , vital sign ECG examination ( eg , atrial fibrillation ) preclude continued initiation treatment bapineuzumab participation study Screening visit brain MRI scan ( MRI Study 301 302 Visit 14/Week 71 ) indicative significant abnormality approve medical monitor prior enrollment Current use experimental medication AD ( bapineuzumab ) experimental medication , herbal preparation contain Ginko biloba , anticoagulant ( except use aspirin 325mg/day less , Plavix , Persantine stroke )</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mild moderate Alzheimer 's disease</keyword>
</DOC>